Related Experiment Video
Updated: Feb 6, 2026
04:59
Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
1.6K
[Inhaled Triple Therapy in Severe Chronic Obstructive Pulmonary Disease (COPD)].
A Gillissen1, M Paparoupa2, D Frings2
1Med. Klinik III (Innere Medizin/Pneumologie), Kreiskliniken Reutlingen/Ermstalklinik, Reutlingen-Bad Urach.
Pneumologie (Stuttgart, Germany)
|August 29, 2018
Summary
Triple inhaler therapy for COPD, combining long-acting beta-agonists, muscarinic antagonists, and inhaled corticosteroids, significantly improves lung function and quality of life in severe patients.
Area of Science:
- Pulmonology
- Pharmacology
- Respiratory Medicine
Background:
- Chronic obstructive pulmonary disease (COPD) involves persistent airflow obstruction due to irritant exposure.
- Fixed-dose combinations of long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA) are standard COPD treatments.
- LABA/inhaled corticosteroids (ICS) are effective for patients with frequent exacerbations.
Purpose of the Study:
- To evaluate the clinical utility of triple combination therapy (LABA/LAMA/ICS) in COPD patients.
- To assess the efficacy of fixed-dose triple inhaler formulations compared to dual therapies and single agents.
Main Methods:
- Analysis of recent clinical trials involving fixed-dose triple inhalers (fluticasone furoate/vilanterol/umeclidinium and beclometasone/formoterol/glycopyrronium).
- Comparison of triple therapy outcomes against LABA/ICS, LABA/LAMA, and monotherapy comparators.
Main Results:
- Triple fixed-dose inhalers significantly reduced COPD exacerbation rates.
- Patients experienced improved lung function, reduced dyspnea scores, and enhanced quality of life.
- These benefits were observed in selected COPD patients, particularly those in groups C and D.
Conclusions:
- Fixed-dose triple inhaler therapies (beclometasone/formoterol/glycopyrronium and fluticasone furoate/vilanterol/umeclidinium) are approved for COPD management.
- Triple therapy offers superior benefits over dual therapies and monotherapy for specific COPD patient groups.
- These formulations represent a significant advancement in managing severe and unstable COPD.
Related Concept Videos
01:24Chronic Obstructive Pulmonary Disease
2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.6K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.6K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.8K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.2K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.2K
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
5.2K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
5.2K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.7K